Back to resources

Thought Leadership Expertise

Publications

Straight From the Horse’s Mouth

Regulatory Roundup

Best practices in preclinical development of cell therapy products

Anthony Davies considers the possibility of a new CMC norm in this BPI article

COGS crisis: Cell therapy sector must rethink CMC, says expert

The long road to affordability: a cost of goods analysis for an autologous CAR-T process

Finding closure: Lowering the costs of cell and gene therapies

Manufacturing costs the ‘biggest threat’ to cell and gene therapies

2017: The Dawning of Cell and Gene Therapies

Product approvals and a regulatory focus on regenerative medicines have made 2017 a breakthrough year for cell and gene therapies, say consultants.

Join the Quarter Horse Newsletter

We’ll send you a quarterly newsletter all things DHC!

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.